SLC16A3 links tumor metabolism to therapeutic opportunities in hepatocellular carcinoma

Zhiyan Li, Zeyu Zhou, Shuwei Liang, Hao Liu, Qiyu Sun, Jian Li · 2026

Read SLC16A3 links tumor metabolism to therapeutic opportunities in hepatocellular carcinoma by Zhiyan Li, Zeyu Zhou, Shuwei Liang, Hao Liu, Qiyu Sun, Jian Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13462551.txt.

Description

Zhiyan Li and co-authors review, in a 2026 article, a lactate-shuttling protein called SLC16A3, also known as MCT4, as a driver and target in liver cancer. Liver cancer remains lethal, with high rates of return, spread, and drug resistance. Tumors rewire their fuel use, and this protein helps dump acid so cancer cells keep burning sugar fast. It runs high in cancers and tracks with aggressive behavior.

The review gathers evidence on how the protein fuels tumor growth, invasion, spread, immune escape, and resistance in liver cancer, and on the signaling routes it touches. High levels mark worse outlook, giving it prognostic value. Blocking it could starve tumors of their metabolism and reopen them to therapy. The authors frame the protein as a window into tumor metabolism and a target. They call for strategies built around it to improve outcomes in liver cancer.

Catalog record

CREATORZhiyan Li, Zeyu Zhou, Shuwei Liang, Hao Liu, Qiyu Sun, Jian Li
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE18039
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13462551

Browse the full library · About the Tower of Babel